Delpharm, a CDMO, has reached an agreement with the Government of Canada to modernize its injectable manufacturing facility in Boucherville.

This announcement ensures that Delpharm will maintain its Boucherville site within Canada, helping to secure the local supply chain for sterile injectable medicines. The Boucherville plant currently produces 20 of the 100 critical medicines vital to the Canadian healthcare system, making it a key player in supplying essential generic products for surgery and intensive care nationwide.

The signing of a 10-year agreement between Delpharm and Sandoz establishes a foundation for ensuring a stable and reliable supply of critical medicines for Canadians, supporting the country’s healthcare autonomy amid global supply chain disruptions.

This modernization plan represents a total investment exceeding $140 million and will preserve over 500 highly skilled jobs in Quebec. Scheduled to run until 2031, the plan includes expanding the site, installing a new filling line, and upgrading existing equipment to comply with new Health Canada standards. Ultimately, 95% of the equipment will be replaced.

Mathieu Grondin, Site Director, said, “This transformation will make our site a world-class facility, in addition to significantly increasing our production capacity and competitiveness. The injectable medications we produce at the site for Sandoz are necessary in almost all surgeries performed in Canada and used to treat patients in intensive care units. This reality makes the Sandoz-Delpharm partnership an essential component for the proper functioning of the country’s healthcare system. On behalf of all employees, I would like to acknowledge the support of the federal government as well as the trust of our client Sandoz. This success is the result of our joint commitment, without which this project could not have materialized.”

Stéphane Lepeu, Chief Commercial Officer at Delpharm, said, “This investment enhances the appeal of our Boucherville site, recognized as our center of expertise in sterile and biological products for the North American market.”